第一单位：
Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA.
作者：
Sara A,Walton [1]
;
Justin J,Kim [1]
;
Francesco,Paoloni [1]
;
Jean W,Liew [2]
;
Danielle,Haradon [1]
;
Jessica,Haradon [1]
;
Kathryn W,Miller [1]
;
Paul K,Paik [3]
;
Jamie E,Chaft [3]
;
Mark G,Kris [3]
;
Robert,Hsu [4]
;
Sarina A,Piha-Paul [5]
;
Julia K,Rotow [6]
;
Pasi A,Jänne [6]
;
David A,Barbie [6]
;
Lynette M,Sholl [7]
;
Steven G,DuBois [8]
;
Glenn J,Hanna [9]
;
Geoffrey I,Shapiro [10]
;
Christopher A,French [7]
;
Jia,Luo [6]
作者单位：
Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA.
[1]
Boston University Chobanian and Avedisian School of Medicine, Boston, MA.
[2]
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, NY.
[3]
Division of Medical Oncology, Department of Internal Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA.
[4]
Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX.
[5]
Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA.;Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
[6]
Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
[7]
Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA.
[8]
Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.;Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, MA.;Department of Medical Oncology, Center for Cancer Therapeutic Innovation, Dana-Farber Cancer Center, Boston, MA.
[9]
Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.;Department of Medical Oncology, Center for Cancer Therapeutic Innovation, Dana-Farber Cancer Center, Boston, MA.
[10]
DOI
10.1200/PO-25-00526
PMID
41348986
发布时间
2026-03-07
换一批
